RT Journal Article
SR Electronic
T1 Gut microbiome composition is predictive of incident type 2 diabetes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.10.21266163
DO 10.1101/2021.11.10.21266163
A1 Ruuskanen, Matti O.
A1 Erawijantari, Pande P.
A1 Havulinna, Aki S.
A1 Liu, Yang
A1 Méric, Guillaume
A1 Inouye, Michael
A1 Jousilahti, Pekka
A1 Salomaa, Veikko
A1 Jain, Mohit
A1 Knight, Rob
A1 Lahti, Leo
A1 Niiranen, Teemu J.
YR 2021
UL http://medrxiv.org/content/early/2021/11/11/2021.11.10.21266163.abstract
AB OBJECTIVE To examine the previously unknown long-term association between gut microbiome composition and incident type 2 diabetes in a representative population cohort.RESEARCH DESIGN AND METHODS We collected fecal samples of 5 572 Finns (mean age 48.7 years, 54.1% women) in 2002 who were followed up for incident type 2 diabetes until Dec 31st, 2017. The samples were sequenced using shotgun metagenomics. We examined associations between gut microbiome compositions and incident diabetes using multivariable-adjusted Cox regression models. We first used the Eastern Finland sub-population to obtain initial findings and validated these in the Western Finland sub-population.RESULTS Altogether 432 cases of incident diabetes occurred over the median follow-up of 15.8 years. We detected 4 species and 2 clusters consistently associated with incident diabetes in the validation models. These 4 species were Clostridium citroniae (HR, 1.21; 95% CI, 1.04-1.42), C. bolteae (HR, 1.20; 95% CI, 1.04-1.39), Tyzzerella nexilis (HR, 1.17; 95% CI, 1.01-1.36), and Ruminococcus gnavus (HR = 1.17; 95% CI, 1.01-1.36). The positively associated clusters, cluster 1 (HR, 1.18; 95% CI, 1.02-1.38) and cluster 5 (HR, 1.18; 95% CI, 1.02-1.36), mostly consisted of these same species.CONCLUSIONS We observed robust species-level taxonomic features predictive of incident type 2 diabetes over a long-term follow-up. These findings build on and extend previous mainly cross-sectional evidence and further support links between dietary habits, metabolic diseases, and type 2 diabetes that are modulated by the gut microbiome. The gut microbiome could potentially be used to improve risk prediction and to uncover novel therapeutic targets for diabetes.Competing Interest StatementThe authors disclose the following potential conflicts-of-interest: T.J.N. has received speaking honoraria from Servier. V.S. has consulted for Sanofi and received honorarium from this company. He also has ongoing research collaboration with Bayer AG, all unrelated to this study.Funding StatementThis research was supported in part by grants from the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, the Finnish Medical Foundation, the Sigrid Juselius Foundation, and the Academy of Finland (#338818 to M.O.R.; #321356 to A.S.H.; #295741, #307127 to L.L.; #321351 to T.J.N.). Additional support was provided by Illumina, Inc. and Janssen Pharmaceutica through their sponsorship of the Center for Microbiome Innovation at UCSD.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Coordinating Ethics Committee of the Helsinki University Hospital District approved the study protocol for FINRISK 2002 (Ref. 558/E3/2001).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source code used to analyze the data and produce our results is included in the Supplementary Information. Due to sensitive health information of individuals, the datasets analyzed during the current study are not public, but are available based on a written application to the THL Biobank as instructed in: https://thl.fi/en/web/thl-biobank/for-researchers